VIR News and Press, Vir Biotechnology Inc. From 02/20/24

2024-02-20 16:33:24 ET More on Vir Biotechnology Sticking With Vir Biotechnology JP Morgan cuts Vir to neutral, cites hepatitis drug franchise concerns Vir Biotechnology to shed 12% of workforce as part of corporate restructuring Read the full article on Se...

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Executive Vice President, and Chief Medical Officer, Phil Pang, M.D., Ph.D., has decided to leave the company at the end of March 2024 to spend more time with his family. The Company has initiated a search for a successor. “Phi...

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the fourth quarter ended December 31, 2023, on February 22, 2024. The Company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on Februa...

2024-01-29 14:19:18 ET More on Vir Biotechnology Sticking With Vir Biotechnology Vir Biotechnology: A Relentless Slide In The Stock, Unresponsive To Positive Developments Vir Biotechnology, Inc. (VIR) Q3 2023 Earnings Call Transcript Vir Biotechnology to shed...

2024-01-17 15:20:13 ET Summary Today, we revisit Vir Biotechnology, Inc. for the first time in nearly a year. The stock took a tumble in July on the back of the trial setback, but the company has multiple shots on goal within its advancing pipeline. The company also has some $...

2024-01-12 10:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-12-29 03:55:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-12-16 04:30:00 ET Summary The Russell 2000 is experiencing an earnings recession, with negative growth expected to continue into Q4. Q3 earnings season saw a positive surprise, with blended earnings growth improving by 430 bps to -9.9% y/y. Earnings and revenue momentum l...

2023-12-13 17:41:15 ET More on Vir Biotechnology Vir Biotechnology: A Relentless Slide In The Stock, Unresponsive To Positive Developments Vir Biotechnology, Inc. (VIR) Q3 2023 Earnings Call Transcript Vir Biotechnology: A Beaten Up Biotech With A Large Margin Of Saf...

– Reinforcing strategic focus on chronic hepatitis delta and chronic hepatitis B clinical programs and antibody platform to target infectious diseases, autoimmune diseases, and oncology – – Reducing workforce by approximately 12% and consolidating geographic footprint...